BridgeBio Pharma company profile
Company profile
BridgeBio Pharma has 1,081 employees and is headquartered in Palo Alto, United States.
With 1,081 employees and revenue of 502.1 million USD in the fiscal year ended December 2025, BridgeBio Pharma discovers, develops and delivers medicines for patients with genetic diseases. Its offerings include Attruby, an oral treatment for cardiomyopathy linked to wild-type or transthyretin-mediated amyloidosis, and NULIBRY, an intravenous form of fosdenopterin for molybdenum cofactor deficiency. Late-stage candidates target achondroplasia and hypochondroplasia with low-dose infigratinib, hypocalcemia and hypoparathyroidism with encaleret, and LGMD2I with BBP-418, while the gene therapy BBP-812 addresses Canavan disease. Partners include Bayer Consumer Care, Alexion, Novartis and Leland Stanford Junior University.
The company recorded a net loss of 724.9 million USD in the same fiscal year. Founded in 2015, it is based in Palo Alto, California, and its programs also span mendelian and oncology conditions as well as gene therapy.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 3160 Porter Drive, 94304, Palo Alto
- Employees
- 1,081
- Chief executive
- Neil Kumar
- Founded
- 2015
- Fiscal year
- January - December
- Listing
- BBIO · NASDAQ
- Currency
- USD
- ISIN
- US10806X1028
- Website
- bridgebio.com
BridgeBio Pharma and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| BridgeBio PharmaBBIO | United States | $15.25B | 1,081 | -37.3% | — |
| Jazz PharmaceuticalsJAZZ | United States | $15.5B | 2,890 | 27.4% | 71.5 |
| ExelixisEXEL | United States | $16.84B | 1,077 | 40.2% | 20.7 |
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
| Bio-TechneTECH | United States | $11.44B | 3,000 | 21.7% | 66.8 |
| Halozyme TherapeuticsHALO | United States | $11.43B | 423 | 56.7% | 25.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
